Ultrahuman M2 Live Launched For Non-Prescription Glucose Tracking And Metabolic Insights

Ultrahuman is bringing its M2 Live metabolic health platform to the United States, adding direct glucose tracking through Abbott’s Lingo continuous glucose monitor. The launch gives users access to real-time glucose trends inside the Ultrahuman app without needing a prescription, positioning the service for health-conscious adults and people monitoring early metabolic risk.

The platform is built around a subscription model, with CGM sensors starting at $99 per month. Each Lingo biosensor is designed to be worn for up to 14 days, depending on use and wear conditions. Ultrahuman says M2 Live will be available in the US in the coming weeks through its website.

M2 Live brings Glucose Data into Ultrahuman’s Health Ecosystem

M2 Live is not just a standalone glucose feed. Ultrahuman is combining CGM readings with data from its Ring wearable, Blood Vision biomarker testing and more than 100 metabolic markers. The aim is to show users how food, exercise, sleep, stress and recovery may influence glucose behaviour through the day.

The company’s Jade AI system processes these signals and turns them into app-based insights. Users can view glucose spikes, meal responses and activity-linked fuel use. Ultrahuman also offers scoring tools such as Metabolic Score, Food Score and Fueling Score to make patterns easier to interpret over time.

“M2 Live removes the friction of needing a physician for access to glucose data and insights,” said Hussain Ahamed, who leads strategic partnerships in the Americas at Ultrahuman.

Why Non-prescription CGM Access Matters

Continuous glucose monitors were originally associated mainly with diabetes care. In the US, newer over-the-counter or non-prescription CGM products are now expanding the category into wellness and preventive health tracking. These products are generally meant to support lifestyle awareness, not replace medical advice, diagnosis or treatment for diabetes.

For users, the appeal is context. A single glucose reading can be hard to act on. Continuous data can show how the body responds after specific meals, poor sleep, late-night eating or workouts. That can help users identify repeat patterns and make more informed changes to diet, timing and activity.

Ultrahuman first entered non-prescription CGM-based wellness tracking in 2021. With M2 Live, it is trying to deepen that model by linking glucose with broader physiological signals. The company also operates OGDb, an open glucose database that uses anonymised user data to study food-linked glucose responses across populations.

Ultrahuman says its metabolic scoring approach has been assessed through multi-site clinical studies and peer-reviewed research, including work involving institutions such as Stanford University and the Mayo Clinic. The wider test for M2 Live will be whether users can convert continuous insights into sustainable health behaviour, rather than treating glucose tracking as another dashboard.